Early Detection Research Network

Lung Reference Set A Application: Dawn Coverley- University of York (2011)

Lung Ref Set A App: Coverley (2011)
341
Coverley, DawnUniversity of York
Feng, ZidingFred Hutchinson Cancer Research Center
Ciz1
No design specified.
Proteomics
[u'Lung and Upper Aerodigestive Cancers Research Group']

A variant of the nuclear matrix factor Ciz1 is prevalent in lung cancer cell lines and tumours, but not in adjacent lung tissue, giving rise to a protein that is stable enough to be detected in just one ul of plasma. This project evaluates the potential of variant Ciz1 as an early detection tool for lung cancer, using variant-selective antibodies.

There are four primary clinical questions to be addressed in the pre-validation study: 1) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current clinical tests (CT scan and/or PET scan) in the diagnostic evaluation of pulmonary nodules with a goal of reducing invasive tests (PET or tissue biopsy) or futile thoracotomies; 2) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current tests (CT scan and/or PET scan) in the early diagnosis/detection of lung cancer in high risk individuals, with a goal of reducing invasive tests (PET or tissue biopsy) or futile thoracotomies and more importantly, missed cures; and 3) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current clinical tests (CT scan, PET scan and biopsies) in the staging of lung cancer; and, 4) Whether b-variant Ciz1 as a single plasma biomarker has the potential for adding value to current clinical tests (e.g., CT scan, PET scan and biopsies) in determining prognosis of lung cancer patients; and, A Secondary clinical question is whether b-variant Ciz1 as part of a panel of biomarkers has the potential for adding value to one or more of the above primary clinical utilities.
Provide adequate detail concerning how statistical analysis of your data generated from the Reference Set(s) samples will be performed and a justification that the requested References Set(s) is/are large enough to demonstrate the utility of the biomarker. Describe the statistical resources at your disposal. If you require statistical support, the EDRN/SPOREs can assist you with this.
No Data Received at DMCC. Assay didn't work well on the samples provided.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.